| Management target | Revenue 32.0% FY28 |
|---|
| Revenue growth | 13% YoY overall; 17% YoY Ex-US. |
|---|---|
| Margins | Gross margins guided to stay in 58-60% range. |
| Demand visibility | Strong specialty customer demand; Ex-US underlying demand remains healthy. |
| Management confidence | High on US growth levers (nasal, transdermal, films). |
Growth
Q1 FY27 revenue grew 13% YoY; Ex-US markets grew 17%. Gross margin expanded 60 bps to 60.9%.
Outlook
Targeting $375m North America revenue by FY28. Expecting 10 launches by March 2027; capex guided at ₹2.5bn-₹3bn annually.
Risks
Geopolitical volatility in Middle East, elevated freight costs (₹131m impact), and US generic pricing competition.
Last quarter's promises, checked
Delivered
- Gross margins 58-60% → delivered 60.9% (= BEAT)
- EBITDA margins 18-20% → delivered 18.2% (= BEAT)
- Sequential Q-on-Q growth → delivered Q1 growth (= BEAT)
Partly delivered
- 10 launches for fiscal year → 2 delivered in Q1 (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: STAR. Summary written with AI assistance from the document.
Strides Pharma Science Ltd: key numbers
- Share price
- ₹1,184.90
- Market cap
- ₹10,922 Cr
- Revenue (annual)
- ₹4,859 Cr
- Net profit (annual)
- ₹556.2 Cr
- P/E (TTM)
- 17.8×Sector 50.4×
- Promoter holding
- 27.91%+0.00% QoQ
- FII holding
- 28.40%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Strides Pharma Science Ltd
All →Strides Pharma Science Business Update
Strides Pharma Science received a Form 483 with three observations following a routine USFDA inspection at its Alathur formulations facility. The company will respond within stipulated timelines.
Strides Pharma Science Investor Presentation: Key Takeaways
Strides Q1FY27 revenue grew 13% YoY to ₹12,654m, led by a 17% surge in Ex-US markets. Operational PAT stood at ₹1,231m.
Strides Pharma Science Q1 FY27 Results: Net Profit ₹165.5 Cr, Up 56.7% YoY
Strides Pharma Science Ltd reported revenue from operations of ₹1,265 Cr (+13.0% YoY) and net profit of ₹165.5 Cr (+56.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹165.5 Cr · +56.7% YoY
Strides Pharma Science Earnings Call: Key Takeaways
Strides Pharma reported its highest ever EBITDA and operational PAT for FY26, driven by significant geographical diversification and a structural shift toward non-U.S. markets.
Strides Pharma Science Earnings Call: Key Takeaways
Strides delivered strong FY26 performance with Revenue at ₹48,587m, up 6.4%, and Operational PAT at ₹5,181m, growing 50% YoY driven by Ex-US market efficiency.
Strides Pharma Science Q4 FY26 Results: Net Profit ₹129.3 Cr, Up 51.1% YoY
Strides Pharma Science Ltd reported revenue from operations of ₹1,324 Cr (+11.2% YoY) and net profit of ₹129.3 Cr (+51.1% YoY) for Q4 FY26.
- Key figure
- Net profit ₹129.3 Cr · +51.1% YoY